Inspired by bioacHve natural spiroketals, spirocyclic rigidified structures have demonstrated to be privileged scaffolds for the design of new tool compounds endowed with diversified biological acHviHes. We synthesised the natural-like spiroketal, 2-hydroxy-8-methyl-1,7-dioxaspiro[5.5]undec-3-en-5-one (5) that showed a potent anHcancer acHvity against human cancer cells of different nature and histotype. 1 In order to confirm the therapeuHc potenHal of this molecule we verified in vitro and in vivo, in a syngenic murine melanoma model, that our product is able to induce cancer regression and growth inhibiHon. The synthesis of the spiroketalic stereoisomeric mixture 5 a,b was carried out by using a two steps procedure based on 2-furyl ketone oxidaHon-rearrangement method. Because, in our previous experiments, the inhibiHon acHvity of the enanHomers was comparable, the steroisomeric mixture 5 a,b was used as such for in vitro and in vivo experiments.
• CONCLUSION:
We have idenHfied the spiroketal 5 a,b as a new promising anHcancer agent with in vivo acHvity on a murine melanoma model. Compound 5 a,b showed potent dose-dependent anHcancer efficacy in syngenic murine model (C57Black mice) of melanoma, suppressing cancer growth by an average of 90% at a dose of 5 mg/kg by one intra-peritoneum administraHon at alternate days for 15 days. It also displayed high anHcancer acHvity in the B16 cells in vitro with nanomolar IC 50 value. In addiHon to the proapoptoHc and telomerase inhibiHon acHvity previously observed, the compound 5 a,b has also shown to inhibit cell migraHon and the deterioraHon of the acHn cytoskeleton. Moreover our spiroketal strongly reduces the HIF1α expression that is considered as regulator of mulHple cellular funcHons related to the progression from primary to metastaHc disease. Therefore, although the full mechanism of acHon has yet to be completely elucidated, we can conclude that spiroketal 5 a,b is a promising anHcancer drug candidate for the clinical treatment of melanoma. In the first set of experiments, the effect of spiroketal 5 a,b was evaluated in vitro on B16 cell growth in order to confirm on this murine model, the previously reported efficacy on human cell lines. Moreover, to acquire addiHonal informaHon on the origin of the anHproliferaHve acHvity, we have also studied the role of cell cycle modificaHon, the apoptosis inducHon, the migraHon characterisHcs of B16 cultured cells, the gene expression of the hypoxia inducible factor 1α (HIF1α) in B16 murine melanoma cells and the modificaHon of the acHn structure and cytoskeleton conformaHon induced by 5 a,b .
• IN VIVO ACTIVITY:
The assessment of the in vivo acHvity of the spiroketal 5 a,b in a well-known B16/C57BL/6J syngenic model of murine melanoma was performed. The effect of this compound on cancer growth reported in the Figures, showed a tumor volume reducHon with respect to the control. Percent of growth inhibi.on Reorganiza*on of the cytoskeleton in response to 5a,b (B16 Cells)
